Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Envoy Medical (COCH) over the last 3 years, with Q3 2025 value amounting to $13000.0.

  • Envoy Medical's Other Accumulated Expenses fell 9963.89% to $13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $13000.0, marking a year-over-year decrease of 9963.89%. This contributed to the annual value of $573000.0 for FY2024, which is 1116.28% down from last year.
  • Per Envoy Medical's latest filing, its Other Accumulated Expenses stood at $13000.0 for Q3 2025, which was down 9963.89% from $179000.0 recorded in Q2 2025.
  • Envoy Medical's 5-year Other Accumulated Expenses high stood at $3.6 million for Q3 2024, and its period low was $13000.0 during Q3 2025.
  • Its 3-year average for Other Accumulated Expenses is $817857.1, with a median of $415000.0 in 2025.
  • Within the past 5 years, the most significant YoY rise in Envoy Medical's Other Accumulated Expenses was 3833.33% (2025), while the steepest drop was 9963.89% (2025).
  • Envoy Medical's Other Accumulated Expenses (Quarter) stood at $645000.0 in 2023, then dropped by 11.16% to $573000.0 in 2024, then crashed by 97.73% to $13000.0 in 2025.
  • Its Other Accumulated Expenses stands at $13000.0 for Q3 2025, versus $179000.0 for Q2 2025 and $415000.0 for Q1 2025.